Birinapant ( Generic (investigational compound, no approved brand names) )

Other Medications

Not submitted to EMA

Not available 1 Clinical Trials

Description

Birinapant (also known as Aplitabart, IGM-8444) is an investigational drug currently being studied in clinical trials for various cancers, including colorectal cancer (CRC). It is not yet approved for use in CRC or any other condition. Clinical trials have explored birinapant alone or in combination with other cancer treatments like chemotherapy (e.g., FOLFIRI) and bevacizumab, particularly in patients whose cancer has come back (relapsed) or is resistant to standard treatments (refractory). The goal of these trials is to determine the safety and effectiveness of birinapant in different cancer types and treatment settings. The trials are in early phases (Phase 1), meaning they primarily focus on finding the right dose and assessing safety, rather than proving effectiveness.

Mechanism of Action

Birinapant is designed to target specific proteins involved in cell survival and death pathways, particularly those related to the BCL-2 family. By interfering with these proteins, birinapant aims to promote cancer cell death (apoptosis). The specific molecular details of how it interacts with these proteins are still being investigated in clinical trials.

Side Effects

As birinapant is an investigational drug in early-phase clinical trials Its full range of side effects is still being evaluated. Information from the NCT04553692 trial indicates that side effects are being closely monitored to determine the drug's safety profile. Common side effects observed in early trials of similar drugs can include fatigue Nausea Diarrhea And changes in blood counts But specific data for birinapant in CRC patients is limited as the trials have been terminated.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04553692 Phase 1

Terminated

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

United States, Australia, France, South Korea, Spain

Quick Info

Brand Name	Generic (investigational compound, no approved brand names)
Category	Other Medications
EMA Status	Not submitted to EMA
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.

Birinapant (** Generic (investigational compound, no approved brand names) **)